Prospective, 2-year, open-label study of the safety, efficacy, quality of life and persistence of fingolimod in relapsing remitting multiple sclerosis patients in Argentina

Trial Profile

Prospective, 2-year, open-label study of the safety, efficacy, quality of life and persistence of fingolimod in relapsing remitting multiple sclerosis patients in Argentina

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REAL
  • Most Recent Events

    • 21 Apr 2016 Results of an interim analysis (n=181) presented at the 68th Annual Meeting of the American Academy of Neurology
    • 08 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top